To assess the possible beneficial effects of combined therapy (fluconazole and flucytosine) in the treatment of cryptococcal meningitis in the immunocompromised host, we compared therapy with fluconazole and flucytosine, individually and combined, in the experimental murine model. BALB/c athymic (nu/nu) mice were infected intracerebrally with 150 to 300 CFU of Cryptococcus neoformans. In mortality studies, treatment was initiated 24 h postinfection and continued for 10 to 14 days with either fluconazole (1 to 15 mg/kg of body weight per day), flucytosine (60 to 120 mg/kg/8 h), both drugs, or 0.3% Noble agar (control). Combined Cryptococcal meningitis is one of the most common fungal infections in immunocompromised hosts, especially patients with AIDS (8, 10, 13) . Depending on the definition used, the therapeutic failure rate in these patients is approximately 30 to 50% and the patients frequently have relapses posttreatment (9, 13, 22). Various treatment regimens for cryptococcal meningitis in non-AIDS patients have been evaluated, and to date, the most established scheme is combination chemotherapy with amphotericin B (AmB) and flucytosine (2, 9). However, nephrotoxicity and myelotoxicity are frequent complications (5, 20). The nephrotoxicity induced by AmB leads to a rise in serum flucytosine concentrations, resulting in myelosuppression. This is particularly a problem for AIDS patients, who are frequently already granulocytopenic when antifungal therapy is commenced.
Cryptococcal meningitis is one of the most common fungal infections in immunocompromised hosts, especially patients with AIDS (8, 10, 13) . Depending on the definition used, the therapeutic failure rate in these patients is approximately 30 to 50% and the patients frequently have relapses posttreatment (9, 13, 22) . Various treatment regimens for cryptococcal meningitis in non-AIDS patients have been evaluated, and to date, the most established scheme is combination chemotherapy with amphotericin B (AmB) and flucytosine (2, 9) . However, nephrotoxicity and myelotoxicity are frequent complications (5, 20) . The nephrotoxicity induced by AmB leads to a rise in serum flucytosine concentrations, resulting in myelosuppression. This is particularly a problem for AIDS patients, who are frequently already granulocytopenic when antifungal therapy is commenced.
New azole antimycotic agents have recently been introduced for treatment of crytococcal meningitis. The toxicities of these azole antimycotic agents occur less frequently and are less severe than those associated with AmB (12). If such agents were as effective in treatment as AmB plus flucytosine, they would be the preferred therapy. Fluconazole, a bis-triazole, is one of these new azole antimycotic agents with broad-spectrum activity and is now in clinical use. The compound penetrates well into cerebrospinal fluid and the central nervous system and appears to be especially promising against Cryptococcus neoformans (1, 15, 21) . In a recent comparative therapy study between fluconazole and AmB in AIDS patients with cryptococcal meningitis, the success rate was approximately 50% for each regimen (7) . An additional recent study calls attention to the superiority of AmB plus flucytosine contrasted to fluconazole alone in the therapy of acute cryptococcal meningitis in AIDS patients (14) . However, it is important to note that the number of patients in this study was small in experience because of complicating factors of their underlying disease and cannot be considered conclusive.
The frequent therapeutic failures plus the toxicities of current treatment regimens underline the need (ii) Quantitative culture studies. Mice were randomly assigned to groups of 5 to 9 animals 24 h postchallenge prior to initiation of antifungal therapy. Treatment was given for seven consecutive days. Animals were sacrificed by cervical dislocation 48 h after the last dose. Their brains were removed and homogenized in 0.9% NaCl supplemented with 60 pLg of amikacin per ml and 60 ,ug of piperacillin per ml.
The homogenates were diluted (by serial 10-fold dilutions) to 10-8 in saline containing amikacin and piperacillin (each 60 ,ug/ml). A 0.1-ml quantity of the undiluted homogenate and dilutions was plated on SDA. Culture plates were incubated for 72 h at 37°C. CFU were then counted, and the number of CFU per g of tissue was calculated.
(iii) In vitro studies. MICs and minimal lethal concentrations (MLC) using experimental strain R 89-98t were determined for flucytosine and fluconazole by following procedures previously described (17) .
Drug levels in serum. Serum fluconazole concentrations were determined by a gas-liquid chromatography assay (11) after single oral doses of 15, 5, 2.5, and 1 mg/kg to mice. Groups of three mice were anesthetized and sacrificed by exsanguination at 1, 2, 4, and 8 h postadministration. The sera from each group were pooled, and drug concentrations were measured. The bioassay procedure modified by Bodet et al. (3) was used to measure serum flucytosine concentrations after single oral doses of 60, 80, and 120 mg/kg. Groups of three to four mice were anesthetized and sacrificed by exsanguination at 1 and 3 h postadministration. The bioassay employed cannot reliably measure flucytosine levels of less than 20 ,ug/ml. Statistical analysis. Mortality and quantitative culture studies were analyzed by Bonferroni t test and Tukey's studentized range test (18) . A P value of less than 0.05 was considered significant.
RESULTS
In vitro studies. MICs and MLCs of the fluconazole and flucytosine for the experimental strain of C. neoformans are presented in Table 1 . The MIC and MLC of fluconazole given alone were at least 20-fold higher than the corresponding fluconazole values when combined with flucytosine, except for the 48-h MLCs (80 jig/ml), which were identical.
By using a checkerboard titration system (17) , the MIC of fluconazole decreased from 20 ,ug/ml when given alone to <1.25 ,ug/ml when given with flucytosine. Because flucytosine values were off the scale, it is difficult to precisely define synergism, e.g., a reduction in the MIC or MLC of each drug by 16-fold when used in combination contrasted to In vivo mortality studies. Intracerebral infection of athymic mice with 150 to 300 CFU of C. neoformans caused death of controls mice from days 7 to 15 postinfection. Groups of 9 to 10 animals were treated with each regimen in mortality studies. In Fig. 1 , percent mortality is shown after oral treatment with fluconazole at 5 mg/kg/day, flucytosine at 80 mg/kg/8 h, or combined therapy for 14 days. All drug regimens delayed the time of death significantly compared with the controls although no compound provided total protection. There was no difference in mortality between fluconazole-and flucytosine-treated animals. Combined therapy with both compounds prolonged survival significantly compared with survival of the controls and groups receiving single-drug treatment (P < 0.05 by Tukey's studentized range test). In the next representative experiment (Fig. 2) , when drug dosages were reduced (60 mg/kg/8 h for flucytosine and 2.5 mg/kg/day for fluconazole) and treatment was shortened to 10 days, similar results were obtained. Compared with control mice, all mice treated showed significantly delayed mortality. Fluconazole-and flucytosinetreated groups did not differ in survival time. Compared with mice in single-drug regimen groups, mice which had received both compounds demonstrated delayed mortality (P < 0.05). In the experiment shown in Fig. 3 The fluconazole (Flu) group received S mg/kg/day, the flucytosine (5FC) group was given 80 mg/kg/8 h, the control group received 0.3% Noble agar, and the group given combination therapy received the concentrations just given. There were nine or ten mice per group. P < 0.05 (using Tukey's studentized range test) when combined-treatment group compared with single-drug groups (fluconazole-and flucytosine-treated groups) and control group. P < 0.05 when single-drug regimen groups compared with control group. compared with those of control mice and flucytosine-treated mice (P < 0.05). Although no statistically significant difference was found between combination therapy and fluconazole, the median burden of C. neoformans in brain tissue was reduced at least by a factor of 10 when animals were treated with combined therapy. In all studies, there was no indication of antagonism between the drugs. Days post infection  FIG. 3 . Efficacy of single-drug and combined therapy on percent mortality in murine cryptococcal meningitis after 10 days of treatment. Fluconazole (Flu) was given at 1 mg/kg/day; flucytosine (SFC) was administered at 60 mg/kg/8 h. P < 0.05 comparing combinedtherapy group with control and flucytosine-treated group. P < 0.05 comparing fluconazole-and flucytosine-treated groups with control group. There was one survivor in combined-therapy group on day 30 postinfection. There were 10 animals per group. By using high doses of itraconazole, a synergistic effect was achieved with combined therapy. In contrast, the combination with fluconazole did not alter the results when treatment was given for 5 days and seemed to have antagonistic effects when treatment was given over a 10-day period. If azole antifungal agents are similar in their mode of action, then the results of Polak are internally contradictory and not readily explicable. Also, a study conducted by Craven and Graybill (6) suggested a positive (but not significant) trend of combined therapy with flucytosine and ketoconazole in experimental cryptococcal meningitis. Other investigators demonstrated antagonism of AmB and ketoconazole in a murine model of disseminated aspergillosis after pretreatment with the imidazole (19) . Comparisons among each of those studies and with the present model are difficult because of differences in experimental designs, pathogens studied, drug concentrations, and regimens used.
Athymic mice (used in all experiments) are severely immunosuppressed and the absence of host resistance in these animals is to some extent comparable with the immune status of patients with AIDS. Cryptococcal meningitis is the most common systemic mycotic infection in AIDS patients (8) . Fluconazole has been shown to be effective in the treatment of cryptococcal meningitis in these patients (7, 21) . However, even after extended therapy, the persistence and recurrence rate of the infection is over 50%. The present model suggests a potential new approach for treatment of cryptococcal meningitis in AIDS patients. Combined fluconazole and flucytosine treatment may achieve an increase in therapeutic response with less toxicity than those of currently used regimens.
